Dosing & Uses
Dosage Forms & Strengths
powder for injection
- 1g/vial
Metastatic Islet Cell Cancer of Pancreas
Single agent therapy
- 1000 mg/m² IV qWeek, may increase to no more than 1500 mg/m²
- Risk of azotemia increase with >1500 mg/m²
- Monitor: CBC, LFTs, renal function
Combination therapy
- 500 mg/m²/day IV for 5 days q4-6Weeks
- Monitor: CBC, LFTs, renal function
Renal Impairment
CrCl >50 mL/min: May administer full dose
CrCl: 10-50 mL/min: 75% of regular dose
CrCl: <10 mL/min: 50% of regular dose
Other Indications & Uses
Metastatic islet cell cancer of pancreas
Off-label: carcinoid syndrome
Not recommended
Metastatic islet cell cancer of pancreas
Single agent therapy
1000 mg/m² IV qWeek, may increase to no more than 1500 mg/m²
Risk of azotemia increase with >1500 mg/m²
Monitor: CBC, LFTs, renal function
Combination therapy
500 mg/m²/day IV for 5 days q4-6Weeks
Risk of azotemia increase with >1500 mg/m²
Monitor: CBC, LFTs, renal function
Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Adverse Effects
>10%
Nephrotoxicity (up to 75%)
Vomiting (up to 90% if no antiemetic)
Metabolic changes, including elevated LFTs, increased LDH (25%)
Hypoglycemia (20%)
Myelosuppression (10-20%)
Frequency Not Defined
Confusion Lethargy Depression
Nausea
Fever
Chills
Hematologic toxicity (fatal reported)
Injection site reactions
Decreased liver function
Jaundice
Nail changes
Nephrogenic diabetes insipidus (rare)
Warnings
Black Box Warnings
The drug should be administered under the supervision of an experienced cancer chemotherapy physician in a facility equipped to monitor drug tolerance and to protect and maintain a patient compromised by drug toxicity
Renal toxicity is dose-related and cumulative and may be severe or fatal
Nausea and vomiting may be severe and treatment limiting at times
Liver dysfunction, diarrhea, and hematologic changes reported
Parenteral streptozocin is mutagenic and found to be tumorigenic in some rodents
The physician must weigh risks versus benefits to the patient
Contraindications
Hypersensitivity; pregnancy
Cautions
Risk of severe nephrotoxicity, dose-related & cumulative (ie, >1500 mg/m²/dose may cause azotemia)
Risk of severe nausea/vomiting
Rapid infusion may cause burning sensation
May alter glucose metabolism in some patients
Avoid pregnancy
Pregnancy & Lactation
Pregnancy Category: D
Lactation: not known if excreted in breast milk, do not nurse
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Nitrosurea agent that contains a glucose moiety and interferes with DNA function; alkylates DNA, crosslinks DNA strands, may modify proteins and inhibit enzymes involved in DNA synthesis.
Pharmacokinetics
Half-Life: 35-40 min
Bioavailability: 17-25%
Onset: 17 days (with dose schedule of 1500 mg/m²)
Peak Response: 35 days (with dose schedule of 1500 mg/m²)
Vd: 43.8 L
Metabolism: Liver
Clearance: 478 mcg/min (range 173-718 mcg/min)
Excretion: Urine (60-70%)
Administration
IV Incompatibilities
Y-site: allopurinol, aztreonam, cefepime, piperacillin/tazobactam
IV Compatibilities
Solution: D5W, NS
Y-site: amifostine, etoposide PO4, filgrastim, gemcitabine, granisetron, melphalan, ondansetron, teniposide, thiotepa, vinorelbine
IV Preparation
Reconstitute in 9.5 mL D5W or NS to obtain a 100 mg/mL pale gold solution
Stable for 48 hr at room temp and 96 hr under refrigeration, BUT manufacturer recommends use within 12 hr because no preservatives
IV Administration
Vesicant
IV infusion in >100 mL D5W or NS over 15 min-6 hr
Continuous infusion over 5 days have been given, but may be associated with increased CNS toxicity
Storage
Refrigerate vials
Protect from light
Images
| BRAND | FORM. | UNIT PRICE | PILL IMAGE |
|---|---|---|---|
| Zanosar intravenous - | 1 gram vial |  |
Copyright © 2010 First DataBank, Inc.
Patient Handout
streptozocin intravenous
NO MONOGRAPH AVAILABLE AT THIS TIME
USES: Consult your pharmacist.
HOW TO USE: Consult your pharmacist.
SIDE EFFECTS: Consult your pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.
PRECAUTIONS: Consult your pharmacist.
DRUG INTERACTIONS: Consult your pharmacist.Keep a list of all your medications with you, and share the list with your doctor and pharmacist.
OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center.
NOTES: No monograph available at this time.
MISSED DOSE: Consult your pharmacist.
STORAGE: Consult your pharmacist.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company for more details about how to safely discard your product.
Information last revised July 2016. Copyright(c) 2022 First Databank, Inc.
IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
